In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


IBA renews interest in iSoft merger:

This article was originally published in Clinica

Executive Summary

Australian health information technology company IBA Health has submitted a revised cash offer of £166.3m ($330m), or 69p per share, for medical software supplier iSoft. IBA said it has agreed to buy around 56.6 million shares from iSoft shareholders, representing 24.3% of the company's issued capital. The revised offer trumps a 66p-per-share offer made on July 20 by fellow healthcare IT specialist CompuGROUP, based in Koblenz, German, which valued the deal at about £160m. IBA will receive a conditional investment of Aus$300m ($241m) from Allco Equity Partners on completion of the offer. Oxfordshire, UK-based iSoft claims to be one of the world's leading suppliers of advanced software applications for the healthcare sector, and was the main software supplier to the £12.4bn overhaul of the UK's National Health Service computer system.

You may also be interested in...

Spin-out A Neat Solution For Sanofi’s Manufacturing Millstone

Stada Grabs GSK Brands In Key EU Markets

Stada says it has become a "major consumer healthcare player" after signing a deal to acquire from GSK 15 brands, which generate annual sales in excess of €100m.

Brazil Levels Medtech ICT Tariffs Playing Field

All medtech in Brazil will soon be subject to standardized industrial tariffs and development-related fiscal incentives, following a reform of rules relating to ICT across all industries.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts